Key Takeaways
- Highest-ever PAT despite transit drag: Q2 PAT hit a record ₹58.3 crore even as goods-in-transit delays pushed ~₹100 crores of sales cut-off into Q3, showing underlying demand strength.
- Pharma intermediates are the growth engine: H1 turnover of ₹119.8 crore grew 282% YoY, a cardiovascular molecule entered commercial production in September, and the opportunity pipeline expanded from 8–10 to 12–15 high-conviction candidates.
- Contrast media is a delayed-recovery story: The segment de-grew 11% YoY in Q2 and 31% in H1, hit by one customer’s lower calendar-2024 offtake and Red Sea transit delays; management expects stabilization from Q4 and a return toward last year’s volume.
- Margins held firm, with a narrow band ahead: Gross margin of 57% improved 2% sequentially; management sees blended margin in a 53–55% range for the current product mix, plus or minus 2%.
- What to watch next quarter: Whether the ~₹100 crore sales cut-off actually converts in Q3, the pace of the cardiovascular molecule ramp, and any signal on contrast media customer offtake normalizing.
Pharma Intermediates: The Growth Story
- H1 breakout: The segment delivered ₹119.8 crore in H1 FY25, a 282% jump over H1 FY24, sustaining Q1’s momentum through Q2.
- Cardiovascular molecule goes live: Commercial production for a key cardiovascular-therapy client began in mid-September from the new Plant 6 capacity, with confirmed orders in hand and a ramp expected over the next two quarters.
- Capacity headroom is ample: Plant 6 has enough capacity to absorb current demand and any uptick for the next couple of years, so near-term growth is gated by customer offtake, not by capex.
- Pipeline is widening, not just deepening: After a European conference last month, management now tracks 12–15 very high-conviction opportunities, up from 8–10 previously.
- Month-on-month efficiency gains: Scale-up experience is driving improved efficiencies, and the next two quarters should see the ramp reach customers’ expectations.
VK Singh: "I think the molecule is very well poised to be a blockbuster."
Contrast Media: Delayed, Not Derailed
- Q2 showed sequential recovery, but YoY is still down: Contrast media grew 76% sequentially in Q2 yet de-grew 11% YoY; H1 de-grew 31% versus H1 last year.
- Two distinct headwinds: One customer’s lower offtake for calendar 2024 (a known factor flagged earlier) and Red Sea transit delays that doubled shipment time; the transit impact is a quarter-level delay, not a demand loss.
- Revenue recognition mechanics amplify the lag: Because most contrast media customers use delivery-at-place Incoterms, revenue is booked only when goods reach the customer, making the ~₹100 crore sales cut-off a Q3 event.
- Volume, not price, is the story: Management sees no significant price erosion; volume discounts are generally offset by rupee depreciation, so the entire variance is attributable to volume.
- Recovery timeline: Demand is expected to stabilize from Q4 2025 onward; H2 should improve on better product mix and a new product launch expected in Q4; management believes the segment can come closer to last year’s volume numbers.
- New molecule adds a growth layer: Validation of an iodinated product is complete, with scale-up expected in Q4; a contrast media intermediate for an NCE molecule has entered validation.
Ganesh Karuppannan: "What you should be actually like looking at is more on the product launches and the opportunities what we have on each of these molecules."
Capacity Build-Out: Capex on Track
- Unit 2 expansion live: About 120 KL of capacity added at Ambernath at a cost of ~₹90 crores; commercial supplies commenced last quarter after successful validation batches, with optimal utilization expected in Q3 and Q4.
- Unit 3 Mahad on schedule: New backward-integration capacity for contrast media is expected to commission in Q1 FY26, with an aim to produce a key raw material currently imported.
- Small-volume plant coming: A dedicated small-volume plant at Unit 2 is targeted for commissioning in Q1 FY26, serving proof-of-concept work, regulatory filings, and small GMP validation quantities for innovators’ clinical development.
- Capex guidance maintained: The annual capex plan of ~₹200 crores remains on track; management is also exploring additional manufacturing footprint options.
R&D & New Capabilities
- R&D infrastructure doubled: In the last 12 months, the company doubled its R&D hardware and strengthened its scientific talent pool, with further augmentation planned to match the surge in CDMO RFPs.
- New chemistry platforms added: Pyrophoric chemistry, iodination, an enzymatic platform, and a platform for amino acid derivatives now sit alongside existing capabilities.
- Enzymatic chemistry is the next edge: The company has built and strengthened enzymatic chemistry capability, filed a couple of patents, and is close to commercializing a product using this process, possibly next year; the platform targets both import-substitution and CDMO applications.
- Why enzymatic matters: Chiral-selection chemistry is significantly more effective via enzymatic processes than regular chemical synthesis, giving the platform a structural advantage in certain molecule classes.
VK Singh: "One is that whenever there is a chemistry where there is chiral selection involved, then the enzymatic process is significantly more effective than a regular chemical synthesis process."
Margins & Mix
- Gross margin held at 57%: Up 2% sequentially and flat YoY, supported by stable raw material prices for the top two or three inputs.
- Blended margin outlook is narrow-band: Based on the current portfolio, management expects margins in a 53–55% range, plus or minus 2%, with no guidance beyond that.
- Revenue-recognition lag distorts the P&L: The ₹42 crore increase in stock-in-trade represents raw material cost for goods already shipped but not yet recognized; the associated ~₹100 crore sales cut-off will flow into Q3, making sequential comparisons more meaningful than YoY.
- No segment-level margin disclosure: Management declined to break out margins by segment, offering only the blended estimate for the current product mix.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Contrast media demand stabilization | Demand for customers to stabilize | From Q4 2025 onwards |
| Contrast media volume recovery | Come closer to last year’s volume numbers | FY25 (implied H2 catch-up) |
| Iodinated product scale-up | Scale up after successful validation | Q4 FY25 |
| Unit 2 new capacity utilization | Reach optimal utilization | Q3 and Q4 FY25 |
| Unit 3 Mahad commissioning | Backward-integration capacity for contrast media | Q1 FY26 |
| Small-volume plant commissioning | Ready for proof-of-concept, regulatory filings, clinical-trial supplies | Q1 FY26 |
| Pharma intermediate ramp | Ramp to customers’ expectations on the cardiovascular molecule | Next two quarters |
| Capex | ~₹200 crores annual plan maintained | Ongoing |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹207.1 cr, +28% QoQ and +18% YoY |
| Gross margin | 57%, +2 ppt QoQ, flat YoY |
| EBITDA | ₹69.5 cr, +57% QoQ and +11% YoY |
| EBITDA margin | 33.6% (per an analyst's math), vs ~30% blended in H1 |
| PAT | ₹58.3 cr, +54% QoQ and +22% YoY, highest ever quarterly net profit |
| PAT margin | 28% of total revenues |
| H1 FY25 revenue | ₹371.1 cr, +3% YoY |
| H1 FY25 EBITDA | ₹113.7 cr, -6.4% YoY |
| H1 FY25 PAT | ₹96.1 cr, +4.5% YoY |
| Contrast media revenue (Q2) | +76% QoQ, -11% YoY |
| Contrast media revenue (H1) | ₹177.9 cr, -31% YoY |
| Pharma intermediate revenue (H1) | ₹119.8 cr, +282% YoY |
| Cash and treasury investments | ₹323.3 cr as of Sep 2024, debt-free |
| Dividend paid | ₹1 per share, total ₹17.35 cr, first ever payout |
| Capex guidance | ₹200 cr annually, base case, on track |
| Unit 2 new capacity | 120 KL added at cost of ₹90 cr, commercial supplies commenced mid-Sep |
| Incremental capacity commissioning | 80 KL in same block, validation ongoing, commercial supplies expected Q3 onward |
| Revenue impact of goods-in-transit shift | ~₹60–70 cr shifted from Q1 to Q2 |
| Transit time (contrast media) | 55–60 days, up from 30–35 days pre-Red Sea crisis |